# OnCo record brentuximab-salcl-phase-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/brentuximab-salcl-phase-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "brentuximab-salcl-phase-2", "NCT00866047" ;
  schema:name "Brentuximab vedotin phase 2 in relapsed systemic anaplastic large cell lymphoma (SG035-0004)"@en ;
  schema:alternateName "SG035-0004"@en, "Pro 2012"@en ;
  schema:description "An antibody-drug conjugate aimed at CD30 made the lymphoma shrink in 86 per cent of people with relapsed anaplastic large cell lymphoma, and disappear on scans in more than half."@en ;
  schema:url <https://onco.cc/trials/brentuximab-salcl-phase-2/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00866047>, <https://doi.org/10.1200/JCO.2011.38.0402>, <https://doi.org/10.1182/blood-2017-05-780049> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence-entities" ;
  onco:phase "2" ;
  schema:startDate "2009-03" ;
  onco:cancers <https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/alk-negative-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd30/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:terms <https://onco.cc/terms/orr/>, <https://onco.cc/terms/complete-response/> ;
  onco:trials <https://onco.cc/trials/echelon-2/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-brentuximab-relapsed-salcl-phase-2-jco-2012/>, <https://onco.cc/key-papers/paper-brentuximab-relapsed-salcl-five-year-blood-2017/> .